ADCT · Insider Trading
ADC Therapeutics SA
Every open-market purchase and sale reported by ADCT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | Jose Carmona | Chief Financial Officer | A | +203,700 | — |
| 2026-07-02 | Mohamed Zaki | Chief Medical Officer | A | +213,900 | — |
| 2026-07-02 | Peter J Graham | Chief Legal Officer | A | +221,100 | — |
| 2026-07-02 | Ameet Mallik | Chief Executive Officer | A | +675,000 | — |
| 2026-06-03 | Timothy Coughlin | Director | MIXED | +32,400 | −$38.81K |
| 2026-06-03 | Robert Azelby | Director | MIXED | +32,400 | −$38.81K |
| 2026-06-03 | Jean-Pierre Bizzari | Director | MIXED | +32,400 | −$38.81K |
| 2026-06-03 | Ron Squarer | Director | MIXED | +29,804 | −$46.80K |
| 2026-06-03 | Victor Sandor | Director | MIXED | +32,400 | −$38.81K |
| 2026-06-03 | Peter Hug | Director | MIXED | +42,844 | −$6.64K |
| 2026-06-03 | Viviane Monges | Director | MIXED | +42,404 | −$8.00K |
| 2026-04-02 | Redmile Group, LLC | 10%+ Owner | Sell | −5,880,415 | −$19.64M |
| 2026-02-18 | Lisa Michelle Kallebo | Chief Accounting Officer | MIXED | +57,467 | +$229.29K |
| 2026-02-18 | Peter J Graham | Chief Legal Officer | MIXED | +261,506 | +$1.04M |
| 2026-02-18 | Jose Carmona | Chief Financial Officer | MIXED | +245,720 | +$980.42K |
| 2026-02-18 | Ameet Mallik | Chief Executive Officer | MIXED | +796,769 | +$3.18M |
| 2026-02-18 | Mohamed Zaki | Chief Medical Officer | MIXED | +260,597 | +$1.04M |
| 2025-12-09 | Lisa Michelle Kallebo | Chief Accounting Officer | F | −7,140 | −$23.49K |
| 2025-12-09 | Peter J Graham | Chief Legal Officer | F | −49,508 | −$162.88K |
| 2025-12-09 | Mohamed Zaki | Chief Medical Officer | F | −41,068 | −$135.11K |
| 2025-12-09 | Jose Carmona | Chief Financial Officer | F | −53,236 | −$175.15K |
| 2025-12-09 | Ameet Mallik | Chief Executive Officer | F | −233,146 | −$767.05K |
| 2025-10-28 | RedCo II Master Fund, L.P. | 10%+ Owner | Buy | +7,692,306 deriv. | — |
| 2025-06-17 | Viviane Monges | Director | F | −2,584 | −$9.25K |
| 2025-06-17 | Victor Sandor | Director | F | −12,600 | −$45.11K |
| 2025-06-17 | Ron Squarer | Director | F | −15,184 | −$54.36K |
| 2025-06-17 | Jean-Pierre Bizzari | Director | F | −12,600 | −$45.11K |
| 2025-06-17 | Robert Azelby | Director | F | −12,600 | −$45.11K |
| 2025-06-17 | Peter Hug | Director | F | −2,144 | −$7.68K |
| 2025-06-13 | RedCo II Master Fund, L.P. | 10%+ Owner | Buy | +28,199,501 deriv. | — |
| 2025-06-05 | Peter Hug | Director | A | +40,000 | — |
| 2025-06-05 | Victor Sandor | Director | A | +40,000 | — |
| 2025-06-05 | Viviane Monges | Director | A | +40,000 | — |
| 2025-06-05 | Ron Squarer | Director | A | +40,000 | — |
| 2025-06-05 | Timothy Coughlin | Director | A | +40,000 | — |
| 2025-06-05 | Jean-Pierre Bizzari | Director | A | +40,000 | — |
| 2025-06-05 | Robert Azelby | Director | A | +40,000 | — |
| 2025-05-19 | Hans Peter Wild | 10%+ Owner | J | +9,788,944 | — |
| 2025-05-19 | Thomas Pfisterer | — | J | −451,856 | — |
| 2025-05-08 | Ameet Mallik | Chief Executive Officer | F | −26,758 | −$34.52K |
| 2025-02-14 | Jose Carmona | Chief Financial Officer | A | +240,000 | +$386.40K |
| 2025-02-14 | Ameet Mallik | Chief Executive Officer | A | +650,000 | +$1.05M |
| 2025-02-14 | Mohamed Zaki | Chief Medical Officer | A | +230,000 | +$370.30K |
| 2025-02-14 | Lisa Michelle Kallebo | Chief Accounting Officer | A | +41,900 | +$67.46K |
| 2025-02-14 | Peter J Graham | Chief Legal Officer | A | +220,000 | +$354.20K |
| 2024-12-13 | Jeremy Green | 10%+ Owner | Buy | +200,000 | +$609.00K |
| 2024-12-09 | Peter J Graham | Chief Legal Officer | F | −41,458 | −$129.76K |
| 2024-12-09 | Lisa Michelle Kallebo | Chief Accounting Officer | F | −6,503 | −$20.35K |
| 2024-12-09 | Mohamed Zaki | Chief Medical Officer | F | −37,112 | −$116.16K |
| 2024-12-09 | Jose Carmona | Chief Financial Officer | F | −48,108 | −$150.58K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jeremy Green | 10%+ Owner | 28,762,443 | $49.47M |
| Redmile Group, LLC | 10%+ Owner | 28,096,025 | $48.33M |
| Hans Peter Wild | 10%+ Owner | 9,788,944 | $16.84M |
| Ameet Mallik | Chief Executive Officer | 2,790,870 | $4.80M |
| Jose Carmona | Chief Financial Officer | 938,076 | $1.61M |
| Mohamed Zaki | Chief Medical Officer | 896,317 | $1.54M |
| Peter J Graham | Chief Legal Officer | 841,640 | $1.45M |
| Thomas Pfisterer | Director | 625,755 | $1.08M |
| Peter Hug | Director | 263,344 | $452.95K |
| Viviane Monges | Director | 186,447 | $320.69K |
| Jean-Pierre Bizzari | Director | 151,902 | $261.27K |
| Victor Sandor | Director | 140,686 | $241.98K |
| Ron Squarer | Director | 138,627 | $238.44K |
| Lisa Michelle Kallebo | Chief Accounting Officer | 128,224 | $220.55K |
| Robert Azelby | Director | 112,805 | $194.02K |
| Timothy Coughlin | Director | 72,400 | $124.53K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ADCT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.